Image Ben Hargreaves Patients The high cost of inequality: High US healthcare spend falls ... Healthcare in the US is facing a cost crisis and one part of the puzzle could be to address the inequality that persists within the system. R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures. Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite. R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further. Load more results
Patients The high cost of inequality: High US healthcare spend falls ... Healthcare in the US is facing a cost crisis and one part of the puzzle could be to address the inequality that persists within the system.
R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures.
Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite.
R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
